Screener
CRISPR Therapeutics CRSP Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 18,612 | 18,578 |
| Other current liabilities | 13,113 | 13,113 |
| Total current liabilities | 136,286 | 149,120 |
| Long-term debt | 585,470 | — |
| Operating lease liabilities, net of current portion | 183,560 | 188,168 |
| Other non-current liabilities | 5,948 | 6,142 |
| Total liabilities | 911,264 | 343,430 |
| Commitments and contingencies, see Note 7 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's long-term debt?
- CRISPR Therapeutics (CRSP) reported long-term debt of $585.47M in Q1 2026.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about CRISPR Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude